Commerzbank Aktiengesellschaft FI Buys Shares of 79,378 CVS Health Corporation $CVS

Commerzbank Aktiengesellschaft FI bought a new position in shares of CVS Health Corporation (NYSE:CVS) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 79,378 shares of the pharmacy operator’s stock, valued at approximately $8,212,000.

A number of other large investors have also made changes to their positions in the stock. Handelsbanken Fonder AB increased its holdings in CVS Health by 83.6% in the second quarter. Handelsbanken Fonder AB now owns 1,089,694 shares of the pharmacy operator’s stock valued at $112,729,000 after buying an additional 496,124 shares in the last quarter. State Street Corp boosted its stake in shares of CVS Health by 2.1% during the 4th quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock worth $4,776,182,000 after acquiring an additional 1,245,457 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of CVS Health by 0.3% in the 4th quarter. Legal & General Group Plc now owns 9,309,182 shares of the pharmacy operator’s stock worth $738,777,000 after acquiring an additional 31,249 shares during the period. Deutsche Bank AG grew its holdings in shares of CVS Health by 28.4% in the 4th quarter. Deutsche Bank AG now owns 4,666,495 shares of the pharmacy operator’s stock worth $370,333,000 after acquiring an additional 1,031,998 shares during the period. Finally, Hussman Strategic Advisors Inc. purchased a new position in CVS Health in the 4th quarter valued at approximately $3,333,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Price Performance

CVS stock opened at $93.99 on Tuesday. The stock has a market capitalization of $120.21 billion, a price-to-earnings ratio of 24.87, a price-to-earnings-growth ratio of 0.93 and a beta of 0.61. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74. CVS Health Corporation has a 52-week low of $69.40 and a 52-week high of $110.68. The stock’s fifty day simple moving average is $102.46 and its 200-day simple moving average is $88.41.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The business had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. During the same period in the prior year, the firm posted $1.81 EPS. The company’s revenue was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Equities research analysts expect that CVS Health Corporation will post 8.02 EPS for the current year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were paid a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.8%. CVS Health’s dividend payout ratio (DPR) is currently 70.37%.

Insider Buying and Selling at CVS Health

In other news, Director Larry Robbins sold 1,018,000 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $93.82, for a total transaction of $95,508,760.00. Following the completion of the sale, the director directly owned 5,195,261 shares of the company’s stock, valued at $487,419,387.02. The trade was a 16.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.85% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have commented on CVS shares. Piper Sandler reiterated an “overweight” rating and set a $113.00 target price on shares of CVS Health in a research report on Monday, June 1st. Barclays lifted their price target on CVS Health from $106.00 to $108.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Robert W. Baird set a $107.00 price objective on shares of CVS Health in a research report on Thursday, August 6th. Wells Fargo & Company raised their target price on shares of CVS Health from $103.00 to $123.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Finally, Cantor Fitzgerald lifted their target price on shares of CVS Health from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 7th. Twenty-two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, CVS Health presently has a consensus rating of “Moderate Buy” and an average target price of $106.75.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.